跳至主要内容
临床试验/CTRI/2018/01/011537
CTRI/2018/01/011537尚未招募3 期

To evaluate upshayatmaka effect of Rasnadidashmool kwath in disintegration of etiopathogenesis of Amavata

Ch Brahm Prakash Ayurved Charak Sansthan1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年1月30日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
100
试验地点
1
主要终点
Improvement in DAS-28 Score

研究概览

简要总结

Amavata (rheumatoid arthritis) is one of the dreaded disease that mankind facing day by day. It not only affects the social and economic position of individual and his family but also leads to draining of national resource due to the work hours lost, resulting in diminished production. Amavata (RA) is reported to be 1-2% of general population with male and female ratio 3:1.

Rasanadidahmool kwath mentioned in Chakradutta in Amavata rogadhikara which have the properties of Amahar,  Shothahar, and Shoolhar. and Erandadi kwath as comprative arm mentioned in Bhashajya Ratnavali has also shows the same property. The primary aim of this research is to find out  potency of both drug in Amavata (RA) and which one is better.

Asssesment criteria- 1- Objective parameters like CRP, RA-factor, ESR and other will be assessed before and after treatment.

**2-**Subjective improvement will be assessed by adopting suitable scoring method.

Study type- Randomized comparative clinical trial

Study time- 24 months

Intervention time- 35 days

Sample size- 100 (50 in each group)

Group-A- The trial drug Rasnadidashmool kwath 48gm BD

Group-B- The comparative  drug Erandadi kwath 48 gm BD

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1-Amavata of any dosha Anubandha 2-Diagnosis of Amavata as per symptoms described in Madhav Nidana 3-Diagnosis of Rheumatoid arthritis as per ACR criteria.

排除标准

  • 1-Pregnant women and lactating mother 2-Patients of RA with know case of rheumatic fever juvenile RA, Ankylosing spondylitis 3-Patients of RA with complications like deformity 4-Any other disorder with Amavata.

结局指标

主要结局

Improvement in DAS-28 Score

时间窗: 35 days

Symptomatic relief in cardinal signs and symptoms of patients

时间窗: 35 days

次要结局

  • Subjective improvement in the patients will be assessed by adopting suitable scoring pattern.(Decrease in elevated levels of CRP,ESR,RA factor and other biochemical parameters.)

研究者

发起方
Ch Brahm Prakash Ayurved Charak Sansthan
申办方类型
Other [State Government Ayurvedic College]

研究点 (1)

Loading locations...

相似试验